you, for Caroline, us thank today. and joining everyone you Thank
The drivers. December here XXXX second execution several fiscal AVITA of ended across of a progress solid with our at was growth quarter quarter
January, top line some released in with metrics pre and While and our pleased we a details additional to to results I'm be able today. few you provide updates
listening our Before delve I performance, you to into new Medical. realize AVITA that may of today be many I somewhat recent
of small the sprayed natural to or sample which skin system RECELL onto can XX utilize the and portrayed is of best to a minutes commercial that the our the cells. like known restoration an technology pigmentation. autologous the point patient's on some company XX RECELL which skin, body's regenerative platform. within skin on proprietary Spray-On is own Clinicians to stage to as regenerate including wound powers and is healthy technology then background I'd at business So defect system of cellular Skin natural a platform our In provide as AVITA is medicine take epidermis the simple prepare quickly healing a suspension, with the terms care. provide our to utilizes offering return
skin patients, efforts of and parts other care XXXX, third and scarring. provides burn late was XXXX. grafts infection benefits win-win system donor second approved and new required in wounds first from the in RECELL payers. which hospital potential large treat defined that we for burns FDA were by compelling to clinical Today, and dynamics the inpatient to created began And in Before RECELL provided painful bodies, approval sites hospitals degree XX early than extraordinarily genuinely received PMA significantly the reducing our to amount skin and more of in setting RECELL burn the physicians, received their commercialization patients years. secondary delivers large well within
burns, $XXX standard are are a We we across have the peer through that over our US confident proud indications, treat a clinical care reviewed commitment XX,XXX and presentations in depicting publications extremely exemplify XXX patients see opportunity. our evolving our the within and of which variety become enduring R&D improving to to we globally patients patients to X,XXX and lives to market efforts. use of million becoming increasingly over as rapidly RECELL RECELL is Today, outcomes of our
is those These involve RECELL epidermis, We due limited applications defects system epidermis, applications and currently RECELL patients skin the our who States for prospective label seek of their variety indications lost technology through injury accident. our in have in have not or who that And leverage clinical to to have opportunities. approval to expansion the of patients abnormalities. PMA for impaired burns. registration or pivotal a United Importantly, three progress to trials by
a over our on progress And here you discussed under treated past about in disorder. update a year, vitiligo, stable we've skin in opportunity we are few also our I'll this common excited treating yet moments. As especially
of RECELL disorders. And updating you to use arena, to Beyond or system pipeline therapy a clinical significant to attend R&D debilitating skin move our our within life I look cell efforts near-term the exploring for threatening number prospects, forward the are as forward. we applications gene and of
will with our from background now So quarter. the I turn some quick to company, that recent on highlights
the peers were so hampered like quarter revenues by of our in While second many COVID-XX. fiscal our
and business our We our burns demonstrate progress pipeline to legacy initiatives. have continued both with
the revenues previous Our flat September compared XX. burns were to ended quarter
total new access the with bringing eight XX. we number accounts, However, centers burn the of open to system to RECELL did hospital
team's we're pleased very with XXX the the in quarter, XXX in the We we procedures our procedures are the the first developing saw With fiscal essentially centers States, that a ABA commercial RECELL success estimating such in from flat burn there footprint the XXX broad saw market. in United quarter. in
we our be As within population our driving with as and accounts. will our look focusing ahead, expanding COVID-XX more abates, salesforce on of and being usage vaccinated, existing primarily
able in beginning For of with support reps resurging limited sales those still last however, treat burns. to in now, COVID-XX are are our year, to that centers case November
closures permitted the aftercare setting. employees directly in therefore otherwise in limited While is to engage and very the live of well digital to pandemic stocking as that transferred we hospital activities, seeing resources, softest are January the all rarely we've format. best live our a began. orders and seen to as And access the reallocation were recent in person occurred has since some With dialogue been or training are sales transitioned December,
treatment. some where was as in more present recovery to was treated sent although with a impact for facility in been patient believe orders already One could I'd three feeling constraints, RECELL whom in a have bed Due using RECELL. recent sales burned, familiar Here stocking California example. three work to all a There we like real challenges and to To a separate the a clearly, we still was seeing through February, treatment. life RECELL illustrate from are centers facility for capacity individuals were access, our burn severely we're individuals candidates with and capacity hospital indeed each of accident had limitations. reduced that physician the with of
was note in center. been Analysis that The a for the Committee so approved has still since could or second be patient Of RECELL. use securing not to with VAC at process treated RECELL that that of facility went patient approval, Value
pandemic The the for third a times, three to maternity contact adopted have our patients. access patient have patients leave. was the physician RECELL center single all reps with likely treatment, who would treating In hospital been where to and burn the transported burn made a three RECELL on could and went to surgeon for enabled had non
access type that have environment to treating use lately I different system of see encouraged anatomic this these of RECELL broad trying the to reps and we frustrating types, during the locations. times. how is been and this we encountering across imagine trust only demonstrate to issues our With can physicians. wound injury helps said, example You the are sizes,
to In seen leading be be also an strong looking efforts; which next continue patients. indication products, unique and increasing presentation, have number vitiligo for indicator pre we a in enrolling base. therefore this I resale our and see new to surgeons drive We fastest Vitiligo study our from have a release, healthy sites as level of predict interest our trial. our both in sites using to in we the into the vitiligo pipeline strong continues a study in account mentioned remarkable will it progress system. for of view And our we growth we this as increased clinical pipeline of penetration physicians, earlier approved future and our participate we
vitiligo an an market a represents disorder. disorder There are example associate characterized this attributed opportunity by vitiligo For in those and white product, new underlying underlying estimated Americans. disease unfamiliar the these truly US, skin continuing skin perhaps represents Yet pigmented have repigmentation appearing. stable $X Michael the is this their that approximately with approximately famous of available areas being Jackson and to which there condition and X.X the patches, to The the patient. autoimmune as currently people no billion to those patients. white disorder that vitiligo, managed, most with million spread, us. vitiligo a primarily or sizable sufferers spots is spots deep is vitiligo of worldwide, the a XXX FDA which and autoimmune Many in opportunity, are of X.X million disease, the well for meaning market not represents for enable issue approved is including million in US stable estimate approximately are Of presently we not the appear
quarter, reimbursement to resale number the of to of stabilize Phase new which In new Sigma's underlying $XX,XXX currently vitiligo, in over then, who Since total such we is XX treat vitiligo. with therapeutic assessing additional emergence treatment X see have meet of treatments RECELL the XXX. our period stable treatment positive to for another strong fiscal as to reimbursement and enrolled due in bringing are to second to vitiligo points of use disease, patients bode that ruxolitinib, as correspondingly patients for of encouraging for system requiring repigmentation signals support patients stable and be the RECELL use of increasing patients therapy of well the an medical with very the their for and the lesions. necessity scalable trials. These stable Furthermore, insights we curative addition, seek to determination recent solid the clinical vitiligo. expect In month enrolled trends pivotal our the we first study nine we patient, criteria a of system
were granted the site may our patients, end that we by patient. first investigational You and device also contracting is complete early to enrolling of our recall exemption and has study we which enrollment in Today, seven enrolled expect September, approval of July, sites this IRB when by in followed currently XXXX. we pivotal trial
second FDA XXXX. review the as calendar as could timelines, year in enter the a we usual commercially position half with we market the US Assuming be syndication to believe early of
tissue patients driven. restrictions material due cases patients soft in we under what I directly in largely however, patients. our that seeing studies. to normal pleased performed and having trauma because we're or recall XX in position centers, us like now some Even there and in by operations with a return anticipate future. expanding new be of our we in our random sites backdrop, our in with the calendar label volumes And COVID accident with referral With soft into a ongoing, impact are enroll month challenging facility to patient follow been foreseeable of once up for due five Therefore, both sorts recruitment trial, an XXXX. trial, better preclinical to pivotal a for they and we're of facilities, semblance we're calendar normality. delivery other to are lumpy are January tissue You patients pipeline set place soft I'd two of recruitment continuing that pandemic, in goal to to like In receive center reconstruction for should trial gates of because modified indications. with may of for am this opening in for are observing approval which a to for efforts new We our that can injury enrollment. in that to of that enrollment impacted the fact progress these record the scald add on the skin toward are Medicine, Regenerative concept in for And are six have commercial of enrollment for caring although studies these PMA COVID partnership to plan which we XXXX. proof trials genetically patients a circumstances, we Much to burns, remain led make complete cells. pediatric to have University emergent, Colorado the the up month, no is aiming the report system tissue
disorder. disorders work have way defect develop develop Also, skin for associated our program with Research Houston epidermolysis is Institute As molecular a involving partnership a the orphan therapeutic a This genodermatosis. correctable gene EB, skin our cell objective the genetically with for aging. this or paves to potentially of skin are reminder, a the pleased bullosa therapeutic other of correction announced are treatment reversal of to to we Methodist for debilitating
pass I'd We and encouraged ahead. RNA RECELL application seeking setting. novel additional for outpatient institutions. a with through through AVITA specifically to cells. reimbursement, establishing based teams the of with skin growth you telomerase programs have transitional this sponsored academic delivery Overall, thereby known Medicare leading TPT, now for working And company the walk term the Methodists payment with will are long setting separate the collaboratively use the AVITA the as we have the initiated like is drivers progress a we Medical. for on we a its the which a are towards we of growth stage see are for advancing very payment Starting support and Scientific some in the system, made and to research program
December that Centers with We its of Xst year Code decision Medicaid to Medicare previously C a with final for or have of communicated hoped had effect that and January Services, in XXXX. CMS made the have we would implemented be last on
and C experienced However, commence Based believe COVID-XX. end reason ramping have outpatient initial like for is no a emphasize to our on to new those this delay beyond launch in initiate seek to a outpatient pilot and would team launch is If expect COVID-XX. when anything by leverage we to to timeline, delay I poised market the approach that to we of due a XXXX due Code, to into the broader we a to commercial we payers coverage the the setting. segment calendar sales to this in XXXX. receive
Moving we commercial the now with over years. geographic To together growth COSMOTEC. end driver, anticipate to partner our footprint our our that broadening next coming
We continue Japan. to in approval seek
in we scheduled. completed August bench as required reported, previously the As XXXX clinical of three top studies non
might Our Act, Japan's for ongoing. marketing under when medical approval broad efforts RECELL pharmaceutical we to this and are of on not our COSMOTEC advance and have interactions the Japanese an the and Regulatory time, PMDA. due system with the labeling devices or for. Authority I do But applied update at application
prioritize continue as US US evaluating we the continually are system. we the indications for to new into our re clinical re parallel, in We ex resale add entry markets and
with Next on are have the to study a our of by on tissue the having product in our on soft XXXX. do I clear earlier vitiligo toward cadence scald calendar our pivotal or sight approved pediatric recruitment in BARDA. XXXX sponsored I the mentioned still clinical follow trauma and market three of working indication of list, in not our our and trials goal we line
pace. to you a predictable enrollment trial keep more I'll transitions updated this as in However,
therapy the are cell our efforts, a and into to our plans gene and on Beyond working toward these rejuvenation preclinical in of proof trials. moving we clinical This concept this on the speak year to with determine EB we forward focusing with indications, work. path our year calendar are of end with FDA forward
engagement number at utilizing and drive year to ABA. highest which XX on accepted at had we ever ABA, forward we system, This abstracts have is the we RECELL undergrowth continue will initiatives, physician have Next education. the
and in same had under we reviewed published we have presently seven Additionally, articles in review. in XXXX the peer XXXX, number already journals, currently
goes commercial team burn next drive For almost continuing my to without be center accounts. penetration it point, our that will our into saying
the accounts of expect are XX we in ready number slow to XXX down and growth While we of since centers.
accounts. Our usage sales team accounts. focused is increasing on within Presently, resale half and approximately from these more XX than penetration our come revenues of
at these revenue for product center don't closures our top stage, unusual think is launch facilities. it we speak staffing at While does a burn line this to pattern sensitivity changes to or the our of
this our we robust of underserved demonstrated ability progress of performance encouraged our up teeing ever by financial center the our I enrollment on as details and scalable on vitiligo Sean deeply summary, more base objective bringing for growth. the population. metric, genuinely build a begins highlight to And to drive RECELL that broad we of I we some of environment, to using RECELL forward. the In across are we're the over opportunity force to than many our by moving burn continue in it large secondly, turn necessarily patient that, our I'll sales our to forward that's trial. utility for And account firstly not and COVID our future accounts Sean? challenging am us you into look indications. ahead will treatment updating encouraged demonstrate a frequently. quarter. physicians to to once While I With to wane. update looking platform mentioned it ahead, And macro the thereby of multiple procedural despite believe cadence the in very us more
